

This is a provisional English translation of an excerpt from the original full report.

## **Risk Assessment Report**

### **Dichlobentiazox** (Pesticides)

Food Safety Commission of Japan (FSCJ)  
May 2019

#### **ABSTRACT**

FSCJ established health based guidance values of dichlobentiazox (CAS No.957144-77-3), a fungicide which contains benzothiazole/isothiazole ring based on results from various studies in the risk assessment.

The data used in the assessment include fate in animals (rats), livestock (goats), fate in plants (paddy rice), residues in crops, subacute toxicity (rats, mice and dogs), chronic toxicity (dogs), chronic toxicity/carcinogenicity (rats), carcinogenicity (mice), two-generation reproductive toxicity (rats), developmental toxicity (rats and rabbits), and genotoxicity.

Major adverse effects of dichlobentiazox were suppressed body weight, anemia in dogs, hyperplasia and hypertrophy of bile duct in the liver, and epithelial hypertrophy/hyperplasia of villus in the duodenum. No carcinogenicity, reproductive toxicity, teratogenicity or genotoxicity was observed.

On the basis of various studies, dichlobentiazox (parent compound only) was identified as a relevant substance for residue definition for dietary risk assessment in agricultural product.

The lowest no-observed-adverse-effect level (NOAEL) obtained in all studies was 5.03 mg/kg bw/day in a two-year chronic toxicity/carcinogenicity study in rats. FSCJ specified an acceptable daily intake (ADI) of 0.05 mg/kg bw/day by applying a safety factor of 100 to the NOAEL.

FSCJ judged it unnecessary to specify an acute reference dose (ARfD), since no adverse effects would be likely to be elicited by a single oral administration of dichlobentiazox.

**Table 1. Levels relevant to toxicological evaluation of dichlobentiazo**

| Species | Study                                                                 | Dose<br>(mg/kg bw/day)                            | NOAEL<br>(mg/kg bw/day)                                 | LOAEL<br>(mg/kg bw/day)                        | Critical endpoints <sup>1)</sup>                                                                                                                                                              |
|---------|-----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rat     | 90-day<br>subacute<br>toxicity study                                  | 0, 300, 900, 3 000<br>ppm                         | M: 22<br>F: 74                                          | M: 65<br>F: 263                                | M: Hyaline droplet<br>accumulation in renal tubule<br>cortex and others<br>F: Epithelial villus<br>hypertrophy/hyperplasia of<br>duodenum                                                     |
|         |                                                                       | M: 0, 22, 65, 236<br>F: 0, 25, 74, 263            |                                                         |                                                |                                                                                                                                                                                               |
|         | Two-year<br>combined<br>chronic toxicity<br>/carcinogenicity<br>study | 0, 120, 550, 2 500<br>ppm                         | M: 5.03<br>F: 7.01                                      | M: 23.5<br>F: 31.9                             | FM: Epithelial villus<br>hypertrophy/hyperplasia of<br>duodenum and others                                                                                                                    |
|         |                                                                       | M: 0, 5.03, 23.5,<br>108<br>F: 0, 7.01, 31.9, 144 |                                                         |                                                | (Not carcinogenic)                                                                                                                                                                            |
|         | Two-generation<br>reproductive<br>toxicity study                      | 0, 62.5, 250, 1 000                               | Parent<br>M: 62.5<br>F: 1 000<br>Offspring<br>FM: 1,000 | Parent<br>M: 250<br>F: —<br>Offspring<br>FM: — | Parent<br>M: Suppressed body weight<br>F: No toxicity<br>Offspring<br>FM: No toxicity<br><br>(No effect on reproduction)                                                                      |
|         | Developmental<br>toxicity                                             | 0, 62.5, 250, 1 000                               | Maternal: 250<br>Embryo/fetus:<br>250                   | Maternal: 1 000<br>Embryo/fetus:<br>1 000      | Maternal: Suppressed body<br>weight and decreased feed<br>consumption<br>Embryo/fetus: Delayed<br>ossification (absent ossification<br>of fifth and sixth sternbrae)<br><br>(Not teratogenic) |
| Mouse   | 90-day<br>subacute<br>toxicity study                                  | 0, 100, 450, 2 000<br>ppm                         | M: 65<br>F: 80                                          | M: 315<br>F: 381                               | FM: Epithelial villus<br>hypertrophy/hyperplasia of<br>duodenum and others                                                                                                                    |
|         |                                                                       | M: 0, 14, 65, 315<br>F: 0, 19, 80, 381            |                                                         |                                                |                                                                                                                                                                                               |
|         | 78-week<br>carcinogenicity<br>study                                   | 0, 50, 325, 2 000<br>ppm                          | M: 247<br>F: 258                                        | M: —<br>F: —                                   | FM: No toxicity                                                                                                                                                                               |
|         |                                                                       | M: 0, 5.8, 38, 247<br>F: 0, 6.6, 42, 258          |                                                         |                                                | (Not carcinogenic)                                                                                                                                                                            |
| Rabbit  | Developmental<br>toxicity study                                       | 0, 15, 50, 150                                    | Maternal: 50<br>Embryo/fetus:<br>150                    | Maternal: 150<br>Embryo/fetus: —               | Maternal:<br>Decreased/suppressed body<br>weight, decreased feed<br>consumption and others<br>Embryo/fetus: Not toxic<br><br>(Not teratogenic)                                                |
| Dog     | 90-day<br>subacute<br>toxicity study                                  | 0, 10, 70, 500                                    | FM: 10                                                  | FM: 70                                         | FM: Bile duct hyperplasia in<br>liver                                                                                                                                                         |

| Species                                | Study                           | Dose<br>(mg/kg bw/day) | NOAEL<br>(mg/kg bw/day)                                          | LOAEL<br>(mg/kg bw/day) | Critical endpoints <sup>1)</sup>                                                      |
|----------------------------------------|---------------------------------|------------------------|------------------------------------------------------------------|-------------------------|---------------------------------------------------------------------------------------|
|                                        | One-year chronic toxicity study | 0, 5, 50, 500/200      | FM: 50                                                           | FM: 500/200             | M: Bile duct hypertrophy in liver and others<br>F: Decreased RBC, Ht or Hb and others |
| ADI                                    |                                 |                        | NOAEL: 5.03<br>SF: 100<br>ADI: 0.05                              |                         |                                                                                       |
| The critical study for setting the ADI |                                 |                        | Two-year combined chronic toxicity/carcinogenicity study in rats |                         |                                                                                       |

ADI, Acceptable daily Intake; NOAEL, No-observed-adverse-effect level; SF, Safety Factor;

—, Lowest-observed-adverse-effect level (LOAEL) was not derived;

<sup>1)</sup>, The adverse effect observed at LOAEL